Fig. 2From: Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experiencePFS (a) and OS (b) of patients receiving nal-IRI + 5-FU/LV based on line of therapy. Patients were classified based on the line of advanced-disease chemotherapy when nal-IRI + 5-FU/LV was administeredBack to article page